MK-5172 potassium saltHCV NS3/4a protease inhibitor CAS# 1206524-86-8 |
Related Products
- MK-5172 hydrate
Catalog No.:BCC1763
CAS No.:1350462-55-3
- MK-5172
Catalog No.:BCC1762
CAS No.:1350514-68-9
- MK-5172 sodium salt
Catalog No.:BCC1765
CAS No.:1425038-27-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1206524-86-8 | SDF | Download SDF |
| PubChem ID | 44603530 | Appearance | Powder |
| Formula | C38H50KN6O9S+ | M.Wt | 806 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Grazoprevir potassium salt | ||
| Solubility | DMSO : ≥ 100 mg/mL (124.23 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| SMILES | CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)[N-]S(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1.[K+] | ||
| Standard InChIKey | MVOGOEKATQJYHW-CIAYNJNFSA-M | ||
| Standard InChI | InChI=1S/C38H50N6O9S.K/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27;/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H3,41,42,43,45,47,48);/q;+1/p-1/t21-,22-,24-,29+,30-,31-,38-;/m1./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
IC50 Value: 7.4 nM and 7 nM for genotype 1b and 1a respectively, in replicon system [1]
Target: HCV NS3/4a protease
in vitro: In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a [2].
in vivo: In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose [1].
Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C . Phase1 References: | |||||
MK-5172 potassium salt Dilution Calculator
MK-5172 potassium salt Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.2407 mL | 6.2035 mL | 12.4069 mL | 24.8139 mL | 31.0174 mL |
| 5 mM | 0.2481 mL | 1.2407 mL | 2.4814 mL | 4.9628 mL | 6.2035 mL |
| 10 mM | 0.1241 mL | 0.6203 mL | 1.2407 mL | 2.4814 mL | 3.1017 mL |
| 50 mM | 0.0248 mL | 0.1241 mL | 0.2481 mL | 0.4963 mL | 0.6203 mL |
| 100 mM | 0.0124 mL | 0.062 mL | 0.1241 mL | 0.2481 mL | 0.3102 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50 Value: 7.4nM and 7nM for genotype1b and 1a respectively, in replicon system [1] MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development. in vitro: In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a [2]. in vivo: In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose [1]. Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C . Phase1
Featured Products
- N-Benzylnaltrindole hydrochloride
Catalog No.:BCC6782
CAS No.:1206487-81-1
- 4,4'-Dihydroxy-3,3',9-trimethoxy-9,9'-epoxylignan
Catalog No.:BCN7017
CAS No.:1206464-65-4
- 2beta-Acetoxyferruginol
Catalog No.:BCN7955
CAS No.:1206461-56-4
- Mofegiline hydrochloride
Catalog No.:BCC5412
CAS No.:120635-25-8
- TC Mps1 12
Catalog No.:BCC7974
CAS No.:1206170-62-8
- GLPG0634
Catalog No.:BCC4145
CAS No.:1206161-97-8
- GLPG0634 analogue
Catalog No.:BCC6547
CAS No.:1206101-20-3
- 16-Nor-7,15-dioxodehydroabietic acid
Catalog No.:BCN7295
CAS No.:120591-53-9
- Anastrozole
Catalog No.:BCC4370
CAS No.:120511-73-1
- Desacetyldoronine
Catalog No.:BCN2105
CAS No.:120481-77-8
- SRT3190
Catalog No.:BCC1966
CAS No.:1204707-73-2
- SRT3109
Catalog No.:BCC1965
CAS No.:1204707-71-0
New Products
- Geranyl ferulate
Catalog No.:BCN7078
CAS No.:1206615-69-1
- (RS)-PPG
Catalog No.:BCC6975
CAS No.:120667-15-4
- DMH-1
Catalog No.:BCC5329
CAS No.:1206711-16-1
- 2''-Acetylastragalin
Catalog No.:BCN4810
CAS No.:1206734-95-3
- 1-(3,4-Dihydroxyphenyl)-7-(4-hydroxyphenyl)hept-6-en-3-ol
Catalog No.:BCN7143
CAS No.:1206788-61-5
- LY2801653
Catalog No.:BCC1720
CAS No.:1206799-15-6
- LY2801653 dihydrochloride
Catalog No.:BCC1721
CAS No.:1206801-37-7
- 6-O-Nicotinoylscutebarbatine G
Catalog No.:BCN7296
CAS No.:1206805-30-2
- Bisacurone
Catalog No.:BCN6725
CAS No.:120681-81-4
- Midostaurin (PKC412)
Catalog No.:BCC5350
CAS No.:120685-11-2
- AM679
Catalog No.:BCC1354
CAS No.:1206880-66-1
- Murrayacarpin B
Catalog No.:BCN3577
CAS No.:120693-44-9
Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.
MK-5172 potassium salt,1206524-86-8,Grazoprevir potassium salt,Natural Products,NS3/4a protease, buy MK-5172 potassium salt , MK-5172 potassium salt supplier , purchase MK-5172 potassium salt , MK-5172 potassium salt cost , MK-5172 potassium salt manufacturer , order MK-5172 potassium salt , high purity MK-5172 potassium salt
